Clinical Trials >

Find a Clinical Trial

Find A Clinical Trial

At Torrance Memorial Physician Network Cancer Care we are committed to the advancement of effective new cancer therapy.

Active Trials TRIO-US

The following clinical trials are available at Torrance Memorial Physician Network Cancer Care in coordination with the TRIO-US / Clinical Trials Network. This is a unique opportunity for patients in the South Bay to receive advanced research treatments previously restricted to university cancer centers. TRIO-US / Clinical Trials Network affiliated program auspiciously places Torrance Memorial Physician Network patients into the promising new era of cancer treatment research. All patients enrolled in these trials are treated at our infusion center in Redondo Beach.

The following studies are subject to change by TRIO-US / Clinical Trials Network and the participating pharmaceutical companies and may not be continually or currently open. Enrollment and participation in these studies is voluntary and patients can choose to withdraw at any time and for any reason. All experimental study drugs are provided at no charge.

Each study has precise entry criteria for enrollment because the researchers are attempting to answer a specific treatment question, within a specific clinical parameter, so not all interested patients will be eligible to participate. It is notable that most of the studies involve drugs that are pathway-specific or targeted, which has been a major trend in cancer research over the past decade as the molecular secrets of cancer growth are revealed.

Disease Title Summary Status Investigator
Breast Cancer neoMonarch Lilly JPBY Breast Cancer A preoperative endocrine study for postmenopausal hormone receptor positive breast cancer evaluating the effectiveness of adding a CKD4/6 inhibitor to standard anastrozole (Arimidex). For 4 months before surgery. CKD4/6 inhibitors are active in increasing benefits of aromatase inhibitors in stage 4 breast cancer. Aromatase inhibitors given before surgery result in smaller cancers and lower mastectomy rates. Open/Active David Chan, M.D.
Breast Cancer PUMA NER-6201 Breast Cancer Neritinib is a experimental 2nd generation oral HER2 targeting drug that has reduced relapsed rate after HER2 based chemotherapy in early breast cancer. Patients receive neritinib for one year to monitor tolerance and side effects. Open/Active David Chan, M.D.
Breast Cancer Novartis CLEE011E2301 (MONALEESA-7) Breast Cancer A Phase 3 randomized study of LEE011, a new CDK4/6 inhibitor with tamoxifen or an aromatase inhibitor in combination with goserelin in the treatment of premenopausal hormone receptor positive, HER2-negative, advanced breast cancer. This study evaluates the effectiveness of an experimental targeted drug in improving the endocrine treatment. Open/Active David Chan, M.D.
Breast Cancer TRIO-US B-10 Breast Cancer A phase 2 randomized trial of MuGard for prevention and treatment of mouthsores in women with hormone receptor positive breast cancer receiving treatment with everolimus-endocrine therapy. Afinitor is often used in combination with Aromasin in stage 4 breast cancer. Patients often have uncomfortable mouth sores. This study assesses Mugard in reducing mucositis. Open/Active David Chan, M.D.
Breast Cancer GNE GO29227 (LOTUS) Breast Cancer A randomized Phase 2 multicenter study of ipatasertib (GDC-0068), an inhibitor of AKT, in combination with paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer. Triple negative breast cancers are ER, PR and HER2 negative. The AKT pathway is targeted in this study. Open/Active David Chan, M.D.
Breast Cancer Clovis CO-3810-025 (LUCY) Breast Cancer A Phase 2 multicenter study of oral lucitanib in patients with FGF aberrant metastatic breast cancer. About 15% of breast cancers have the FGFR pathway. This study uses an oral targeted drug to attack that pathway. Open/Active David Chan, M.D.
Breast Cancer Biomarin BMN 673-301/201 (EMBRACA) Breast Cancer A Phase 3 randomized multi-center study of BMN 673 versus Physician’s Choice in BRCA positive with locally advanced or metastatic breast cancer, who have received no more than 2 prior chemotherapy regimens. BMN 673 is an oral PARP inhibitor and PARP pathway is important in BRCA related breast cancers. Open/Active David Chan, M.D.
Breast Cancer

TRIO 020 Breast Cancer

A randomized phase 2 trial of letrozole plus afatinib versus letrozole alone in postmenopausal hormone receptor positive, HER2 negative patients with metastatic disease with low ER expression. Afatinib is approved to treat EGFR positive lung cancer and has activity in breast cancer. Open/Active David Chan, M.D.
Breast Cancer Merrimack MM-302-02-02-03 Breast Cancer A randomized multicenter study of MM-302 plus trastuzumab vs. standard chemotherapy plus trastuzumab in anthracycline naïve patients with locally advanced/metastatic HER2-Positive breast cancer. MM-302 is a new encapsulated anthracycline that targets the HER2 protein. Open/Active David Chan, M.D.
Breast Cancer TRIO-US B-09 Breast Cancer Phase 1b/2 trial evaluating the combination of lapatinib, everolimus and capecitabine for the treatment of patients with HER2-positive metastatic breast cancer with CNS progression after trastuzumab. This study evaluates the effective of using 3 oral drugs in treating HER2 positive breast cancer with brain involvement. Open/Active David Chan, M.D.
Breast Cancer PUMA NER 1301 (NALA) Breast Cancer A study of neratinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer who have received two or more prior HER2-directed regimens in the metastatic setting. This study evaluates 2 oral combinations targeting HER2 in stage 4 breast cancer. Open/Active David Chan, M.D.
GI Cancer Lilly I4T-MC-JVCU (RAINFALL) Gastric Cancer A randomized Phase 3 Study of capecitabine and cisplatin with or without ramucirumab in first-line therapy of patients with metastatic gastric/GE junction adenocarcinoma. This study evaluates a 2nd generation angiogenesis inhibitor in combination with standard chemotherapy for stage 4 cancers of the stomach and lower esophagus. Open/Active Hugo Hool, M.D.
GI Cancer Merrimack 141-07-02-02 (CARRIE) Pancreatic Cancer A randomized Phase 2 Study of MM-141 used in combination with Abraxane and Gemzar in 1st line metastatic pancreatic cancer. The study drug is a bi-specific antibody attacking the IGF pathway. Open/Active Hugo Hool, M.D.
GI Cancer Incyte INCB 18424-362 (JANUS1) Pancreatic Cancer A randomized Phase 3 Study of the JAK1/2 Inhibitor, ruxolitinib in combination with capecitabine in advanced or metastatic cancer of the pancreas who have already had one round of chemotherapy. This 2nd line regimen uses all oral drugs. Open/Active Hugo Hool, M.D.
Lung Cancer AstraZeneca D419A (MYSTIC) NSCLC A phase 3 trial comparing standard platinum based chemotherapy with the addition of single or double immunotherapies with experimental checkpoint inhibitors. This is a key study in moving checkpoint inhibitors earlier in the treatment cycle. Open/Active Thomas Lowe, M.D.
Lung Cancer Clovis CO-1686-020 (TIGER 3) NSCLC A Phase 3 multicenter randomized Study of oral CO-1686 versus single chemotherapy in patients with mutant EGFR non-small cell lung cancer (NSCLC) after previous treatment with EGFR-directed tyrosine kinase inhibitor (TKI) and a platinum doublet chemotherapy. This study evaluates a next generation oral inhibitor of EGFR. Open/Active Thomas Lowe, M.D.
Lung Cancer Lilly I3Y-MC-JPBK (JUNIPER) NSCLC A Randomized Phase 3 Study of abemaciclib versus Erlotinib in patients with Stage IV NSCLC with a detectable KRAS Mutation who have progressed after platinum-based chemotherapy. The study drug is a new CDK4/6 inhibitor. Open/Active Thomas Lowe, M.D.
Head and Neck Cancer AstraZeneca D4193 (HAWK) This is an immunotherapy trial. MED1476 is an experimental antibody checkpoint inhibitor that results in immune destruction across a wide range of cancers. Patients who have relapsed after previous radiation and chemotherapy are eligible. Open/Active Thomas Lowe, M.D.
Head and Neck Cancer AstraZeneca D4193 (Eagle 02) This study evaluates two checkpoint inhibitors that promote the immune system to eradicate cancer. MED1476 alone, or paired with tremelimumab is compared with best standard chemotherapy. Open/Active Thomas Lowe, M.D.
Head and Neck Cancer AstraZeneca D4193 (CONDOR) This is an immunotherapy trial. The checkpoint inhibitor MED1476, the checkpoint inhibitor tremelimumab are given singly or in combination in patients who have progressed after standard chemotherapy. Open/Active Thomas Lowe, M.D.
Lymphoma Cancer "Trio" AstraZeneca D419CC00002 A Phase 3, randomized stud of GS-1101 (CAL-101) in combination with rituximab for previously treated Indolent Non-Hodgkin Lymphoma. This study tests an oral drug combined with an antibody in patients with low grade lymphoma. Open/Active Hugo Hool, M.D.
Bladder Cancer Lilly I4T-MC-JVDC Bladder A Phase 3, randomized study of ramucirumab plus docetaxel in patients with locally advanced or unresectable or metastatic urothelial carcinoma who progressed on or after platinum-based combination chemotherapy. Open/Active Thomas Lowe, M.D.

Active Trials

The following clinical trials are available at Torrance Memorial Physician Network Cancer Care and are not in coordination with the TRIO-US / Clinical Trials Network.

Disease Title Summary Status Investigator
All Solid Tumors LexentBio LB-1985106 Employ genomic detection methodologies to measure the relative amount of tumor-derived nucleic acids in the blood of patients diagnosed with advanced malignancy who are either commencing, currently undergoing or have completed treatment. Open/Active David Chan M.D.
Lung “Vision” Quintiles MS200095-0022 Phase II single-arm trial to investigate Tepotinib in advanced (stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations (SCREENING SITE) Open/Active Andrew Horodner M.D.
Breast mBC "Contessa" Odonate ODO-TE-B301 This is a multinational, multicenter, randomized, open-label, parallel group Phase 3 study. The primary objective is to compare the efficacy of tesetaxel plus a reduced dose of capecitabine versus the approved dose of capecitabine alone based on PFS, as assessed by an Independent Radiologic Review Committee (IRC), in patients with HER2 negative, HR positive, LA/MBC previously treated with a taxane in the neoadjuvant or adjuvant setting. Open/Active Swati Sikaria, MD
Colon Colorectal "Nova" Clinical Genomics CG001 Evaluation of the performance of the Clinical Genomics Colvera blood test in the detection of disease recurrence in patients diagnosed with Colorectal cancer. Liquid biopsy collection. Open/Active David Chan, M.D.
Colon Colorectal "Pascal" Clinical Genomics CG013 Evaluation of the Performance and Sensitivity of the Clinical Genomics Colvera Test in Predicting Recurrence of Colorectal Cancer (Paired Analysis of Sensitivity for Colorectal Cancer using COLVERA : PASCAL) Liquid biopsy collection. Open/Active David Chan, M.D.

Cedars-Sinai

Disease Title Summary Status Investigator
Breast HR+ "monarchE" Lilly I3Y-MC-JPCF The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer. Open/Active David Chan, M.D.
Breast DCIS "Comet" Alliance Foundation Trials, Inc AFT-25 This study looks at the risks and benefits of active surveillance (AS) compared to guideline concordant care (GCC) in the setting of a pragmatic prospective randomized trial for low risk DCIS. Our overarching hypothesis is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AS approach does not yield inferior cancer or quality of life outcomes compared to GCC. Open/Active Swati Sikaria, MD
Liver Hepatocellular "Himalaya" AstraZeneca D419CC00002 This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC. The patients cannot be eligible for locoregional therapy. Open/Active Syed Jilani, MD
Kidney Renal Cell Carcinoma "Cantata" Calithera Biosciences, Inc CX-839-008 This study is a randomized Phase 2 evaluation of CB-839 in combination with cabozantinib versus placebo with cabozantinib in Renal Cell Carcinoma patients with at least one and not more than 2 prior therapies in the advanced or metastatic setting. Open/Active Vanessa Dickey, MD
Tapur “Tapur” Sponsor: ASCO NCT02693535

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.

Treats:

  • CML
  • Leukemia
  • NHL- Non-Hodgkin’s Lymphoma
  • MM- Multiple Myeloma
  • Solid Tumors

More Info Available: WWW.CLINICALTRIALS.GOV
NCT02693535 www.Tapur.org

Open/Active Swati Sikaria, MD